From an implementation perspective, the 10-gene signature (CLIC1, NAP1L1, CBX3, RAN, APOE, CD63, CLTA, SNRPG, FTL, and POMP) could be assessed using RT-PCR or targeted RNA sequencing, making it feasible for integration into clinical testing workflows alongside established prognostic factors to guide treatment decisions throughout the HCC care continuum. This evidence concerns the gene NAP1L1 and hepatocellular carcinoma.